- Home
- FUFU vs VIR Comparison
FUFU vs VIR Comparison
Compare FUFU & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUFU
- VIR
- Stock Information
- Founded
- FUFU 2020
- VIR 2016
- Country
- FUFU Singapore
- VIR United States
- Employees
- FUFU N/A
- VIR N/A
- Industry
- FUFU
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- FUFU
- VIR Health Care
- Exchange
- FUFU NYSE
- VIR Nasdaq
- Market Cap
- FUFU 737.9M
- VIR 724.1M
- IPO Year
- FUFU N/A
- VIR 2019
- Fundamental
- Price
- FUFU $4.32
- VIR $5.50
- Analyst Decision
- FUFU Strong Buy
- VIR Strong Buy
- Analyst Count
- FUFU 1
- VIR 7
- Target Price
- FUFU $7.00
- VIR $33.57
- AVG Volume (30 Days)
- FUFU 234.8K
- VIR 1.4M
- Earning Date
- FUFU 05-19-2025
- VIR 05-01-2025
- Dividend Yield
- FUFU N/A
- VIR N/A
- EPS Growth
- FUFU 379.11
- VIR N/A
- EPS
- FUFU 0.34
- VIR N/A
- Revenue
- FUFU $463,330,000.00
- VIR $74,205,000.00
- Revenue This Year
- FUFU $6.47
- VIR N/A
- Revenue Next Year
- FUFU $59.37
- VIR $17.69
- P/E Ratio
- FUFU $13.04
- VIR N/A
- Revenue Growth
- FUFU 63.08
- VIR N/A
- 52 Week Low
- FUFU $2.32
- VIR $4.95
- 52 Week High
- FUFU $7.39
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- FUFU 45.82
- VIR 35.61
- Support Level
- FUFU $4.13
- VIR $5.32
- Resistance Level
- FUFU $4.70
- VIR $5.73
- Average True Range (ATR)
- FUFU 0.49
- VIR 0.45
- MACD
- FUFU 0.01
- VIR 0.05
- Stochastic Oscillator
- FUFU 46.00
- VIR 32.35
About FUFU BITFUFU INC
BitFuFu Inc is a digital asset mining and cloud-mining service provider that fosters a secure, compliant, and transparent blockchain infrastructure. It provides stable and intelligent digital asset mining solutions, including one-stop cloud-mining services and miner hosting services to institutional customers and individual digital assets.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.